Literature DB >> 17578681

Plasminogen Activator Inhibitor-1 (PAI-1) gene 4G/5G alleles frequency distribution in the Lebanese population.

Dina M R Shammaa1, Amira S Sabbagh, Ali T Taher, Ghazi S Zaatari, Rami A R Mahfouz.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of fibrinolysis. Increased plasma PAI-1 levels play an essential role in the pathogenesis of cardiovascular risk and other diseases associated with thrombosis. The 4G/5G polymorphism of the PAI-1 promoter region has been extensively studied in different populations. We studied 160 healthy unrelated Lebanese individuals using a reverse hybridization PCR assay to detect the 5G/5G, 4G/5G and, 4G/4G genotypes of the PAI-1 gene and the frequencies of the 4G and 5G alleles. We found that 4G/5G genotype was the most prevalent (45.6%) followed by 5G/5G (36.9%) and 4G/4G (17.5%). The frequencies of the 4G and 5G alleles were calculated to be 0.403 and 0.597, respectively. Compared to other ethnic communities, the Lebanese population was found to harbour a relatively high prevalence of the rare 4G allele. This, in turn, may predispose this population to develop cardiovascular diseases and other thrombotic clinical conditions. This study aids to enhance our understanding of the genetic features of the Lebanese population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17578681     DOI: 10.1007/s11033-007-9106-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  36 in total

1.  The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism.

Authors:  W C Hooper; C Lally; H Austin; M Renshaw; A Dilley; N K Wenger; D J Phillips; C Whitsett; P Rawlins; B L Evatt
Journal:  Thromb Res       Date:  2000-08-01       Impact factor: 3.944

2.  High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation?

Authors:  A Taher; I Khalil; A Shamseddine; F El-Ahdab; A Bazarbachi
Journal:  Thromb Haemost       Date:  2001-08       Impact factor: 5.249

Review 3.  Plasminogen activator inhibitor 1 in thrombotic disease.

Authors:  B Wiman
Journal:  Curr Opin Hematol       Date:  1996-09       Impact factor: 3.284

4.  Fibrinolytic gene polymorphism and ischemic stroke.

Authors:  Katarina Jood; Per Ladenvall; Anna Tjärnlund-Wolf; Claes Ladenvall; Maria Andersson; Staffan Nilsson; Christian Blomstrand; Christina Jern
Journal:  Stroke       Date:  2005-09-22       Impact factor: 7.914

5.  The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls.

Authors:  G Endler; W Lalouschek; M Exner; G Mitterbauer; D Häring; C Mannhalter
Journal:  Br J Haematol       Date:  2000-08       Impact factor: 6.998

6.  Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A.

Authors:  N Akar; E Yilmaz; E Akar; F Avcu; A Yalçin; S Cin
Journal:  Thromb Res       Date:  2000-02-15       Impact factor: 3.944

7.  No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age.

Authors: 
Journal:  Circulation       Date:  2003-03-04       Impact factor: 29.690

8.  The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia.

Authors:  Maria Teresa Sartori; Cristina Danesin; Graziella Saggiorato; Daniela Tormene; Paolo Simioni; Luca Spiezia; Giovanni Maurizio Patrassi; Antonio Girolami
Journal:  Clin Appl Thromb Hemost       Date:  2003-10       Impact factor: 2.389

9.  PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction: results from the Stockholm Heart Epidemiology Program (SHEEP).

Authors:  Karin Leander; Björn Wiman; Johan Hallqvist; Margareta Sten-Linder; Ulf de Faire
Journal:  Thromb Haemost       Date:  2003-06       Impact factor: 5.249

10.  Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.

Authors:  H Pannekoek; H Veerman; H Lambers; P Diergaarde; C L Verweij; A J van Zonneveld; J A van Mourik
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

View more
  4 in total

1.  The association between cardiovascular disease gene mutations and recurrent pregnancy loss in the Lebanese population.

Authors:  Hanadi El Achi; Johnny Awwad; Sarah Abou Daya; Sahar Halabi; Sandra Damianos; Rami Mahfouz
Journal:  Mol Biol Rep       Date:  2018-07-04       Impact factor: 2.316

2.  Significance of the use of the ViennaLab "Cardiovascular Disease panel" (CVD) Assay as a reflex test for the "Factor V/II/MTHFR Assay".

Authors:  Rouba Hoteit; Fatmeh Abbas; Ahmad Antar; Rabab Abdel Khalek; Dina Shammaa; Rami Mahfouz
Journal:  Meta Gene       Date:  2013-11-19

3.  High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.

Authors:  Jeanne d'Arc AlBacha; Mira Khoury; Charbel Mouawad; Katia Haddad; Samar Hamoui; Albert Azar; Ziad Fajloun; Nehman Makdissy
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

4.  Genetic risk factors in patients with deep venous thrombosis, a retrospective case control study on Iranian population.

Authors:  Soudabeh Hosseini; Ebrahim Kalantar; Maryam Sadat Hosseini; Shadi Tabibian; Morteza Shamsizadeh; Akbar Dorgalaleh
Journal:  Thromb J       Date:  2015-11-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.